Last reviewed · How we verify
Centre de Recherche Médicale de Lambaréné — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
2 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Benzimidazole Anthelmintic | Benzimidazole Anthelmintic | marketed |
Therapeutic area mix
- Infectious Diseases · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Advanz · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- Epicentre · 1 shared drug class
- Frantz Viral Therapeutics, LLC · 1 shared drug class
- GSK · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centre de Recherche Médicale de Lambaréné:
- Centre de Recherche Médicale de Lambaréné pipeline updates — RSS
- Centre de Recherche Médicale de Lambaréné pipeline updates — Atom
- Centre de Recherche Médicale de Lambaréné pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centre de Recherche Médicale de Lambaréné — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-de-recherche-m-dicale-de-lambar-n. Accessed 2026-05-16.